Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin recepto…
Biotechnology
US, Seattle [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q1 | Q2 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | -17.29 | 5.82 | 7.04 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 4.72 | 1.33 | 1.27 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q1 | Q2 | Δ in % | |
|---|---|---|---|---|
| Book Value | -14.50 | 4.99 | 5.83 | |
| Cash | -16.24 | 4.15 | 4.96 | |
| Capex | 34.05 | < 0.005 | -0.01 | |
| Free Cash Flow | -18.32 | -0.86 | -0.73 | |
| Revenue | -45.54 | 0.01 | 0.03 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q1 | Q2 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | -25.25 | 0.57 | 0.76 | |
| Operating Margin | -114.44 | -72.05 | -33.60 | |
| ROA | -23.78 | -0.14 | -0.11 | |
| ROE | -28.49 | -0.19 | -0.15 | |
| ROIC | -27.98 | -0.17 | -0.13 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of KDNY is permitted for members.
5
Growth
The "Growth Entry" for the Focus of KDNY is permitted for members.
6
Leverage & Liquidity